EP1390052A4 - Inhibition de la kinase jun - Google Patents

Inhibition de la kinase jun

Info

Publication number
EP1390052A4
EP1390052A4 EP02764295A EP02764295A EP1390052A4 EP 1390052 A4 EP1390052 A4 EP 1390052A4 EP 02764295 A EP02764295 A EP 02764295A EP 02764295 A EP02764295 A EP 02764295A EP 1390052 A4 EP1390052 A4 EP 1390052A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
jun kinase
kinase
jun
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02764295A
Other languages
German (de)
English (en)
Other versions
EP1390052A1 (fr
Inventor
Gokhan S Hotamisligil
Michael Karin
Lufen Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
University of California
Original Assignee
Harvard College
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, University of California filed Critical Harvard College
Publication of EP1390052A1 publication Critical patent/EP1390052A1/fr
Publication of EP1390052A4 publication Critical patent/EP1390052A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02764295A 2001-04-24 2002-04-24 Inhibition de la kinase jun Ceased EP1390052A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28596601P 2001-04-24 2001-04-24
US285966P 2001-04-24
PCT/US2002/012687 WO2002085396A1 (fr) 2001-04-24 2002-04-24 Inhibition de la kinase jun

Publications (2)

Publication Number Publication Date
EP1390052A1 EP1390052A1 (fr) 2004-02-25
EP1390052A4 true EP1390052A4 (fr) 2008-10-08

Family

ID=23096452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02764295A Ceased EP1390052A4 (fr) 2001-04-24 2002-04-24 Inhibition de la kinase jun

Country Status (3)

Country Link
EP (1) EP1390052A4 (fr)
CA (1) CA2477842A1 (fr)
WO (1) WO2002085396A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072888A1 (en) 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
US7119114B1 (en) 1999-08-19 2006-10-10 Signal Pharmaceuticals, Llc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US6987184B2 (en) 2001-02-15 2006-01-17 Signal Pharmaceuticals, Llc Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
EP2065383A1 (fr) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Composés d'indazoles et procédés d'utilisation associés en tant qu'inhibiteurs de kinase de protéine
JP4686704B2 (ja) * 2004-08-24 2011-05-25 国立大学法人山口大学 動脈瘤予防および／または治療剤
JP2008513465A (ja) * 2004-09-15 2008-05-01 ザ プレジデント アンド フェロウズ オブ ハーバード カレッジ 肥満及び糖尿病の治療におけるｅｒストレス低減
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
WO2008016995A2 (fr) * 2006-08-01 2008-02-07 Joslin Diabetes Center, Inc. Procédés d'identification de modulateurs de la signalisation de l'insuline
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
CN102676466A (zh) * 2011-03-17 2012-09-19 南京大学 一种突变型jnk1序列及其质粒的应用
ES2724300T3 (es) 2013-09-25 2019-09-10 Univ Cornell Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
WO2015138426A1 (fr) * 2014-03-10 2015-09-17 Croce Carlo M Compositions et méthodes permettant de traiter la cachexie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053927A1 (fr) * 1998-04-17 1999-10-28 Trustees Of Tufts College Procedes pour traiter et prevenir la resistance a l'insuline et les troubles qui y sont lies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2160371A1 (fr) * 1993-04-16 1994-10-27 The Trustees Of Tufts College Methode pour le traitement des symptomes menopausiques et premenstruels
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053927A1 (fr) * 1998-04-17 1999-10-28 Trustees Of Tufts College Procedes pour traiter et prevenir la resistance a l'insuline et les troubles qui y sont lies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AGUIRRE V; UCHIDA T; YENUSH L; DAVIS R; WHITE M F: "The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 12, 24 March 2000 (2000-03-24), pages 9047 - 9054, XP002493212, ISSN: 0021-9258 *
BENNETT B ET AL: "A SELECTIVE INHIBITOR OF JNK THAT MODULATES THE ACTIVATION AND DIFFERENTIATION OF CD4+ CELLS", IMFLAMMATION RESEARCH, BIRKHAEUSER VERLAG, BASEL, vol. 49, no. SUPPL. 02, 1 August 2000 (2000-08-01), pages S102, XP008014580, ISSN: 1023-3830 *
See also references of WO02085396A1 *

Also Published As

Publication number Publication date
EP1390052A1 (fr) 2004-02-25
WO2002085396A1 (fr) 2002-10-31
CA2477842A1 (fr) 2002-10-31

Similar Documents

Publication Publication Date Title
EP1363702A4 (fr) Procedes d'inhibition de kinases
HK1208446A1 (en) Derivatives of uk-2a uk-2a
EP1381598A4 (fr) Nouveaux inhibiteurs de la tyrosine kinase
AU3704101A (en) Kinase inhibitors
MXPA03006420A (es) Diaminotiazoles.
EP1383743A4 (fr) Doubles inhibiteurs de la pde 7 et de la pde 4
HK1066546A1 (en) Trifluoromethylpurines as phosphodiesterase 4 inhibitors
PL373301A1 (en) Phosphodiesterase 4 inhibitors
EP1390052A4 (fr) Inhibition de la kinase jun
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
AU2002323406A1 (en) Tyrosine kinase inhibitors
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
AU2002327534A1 (en) Tyrosine kinase inhibitors
GB0101686D0 (en) Cyclin dependent kinase inhibitors
IL161178A0 (en) MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES
AU2002307475A1 (en) Inhibition of jun kinase
IL156839A0 (en) Use of chromanes
GB2394953B (en) Inhibition of replication factor C
AU2002360614A8 (en) Methods of inhibiting fertility
HU0104370D0 (en) Honeyed schnaps of oerseg
GB0126214D0 (en) Inhibition of hyperproliferation
TW573751U (en) Structure capable of preventing jaming
AU2002246255A1 (en) Jun kinase inhibitors
CA91421S (en) Set of furniture

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHANG, LUFEN

Inventor name: KARIN, MICHAEL

Inventor name: HOTAMISLIGIL, GOKHAN, S.

A4 Supplementary search report drawn up and despatched

Effective date: 20080905

17Q First examination report despatched

Effective date: 20090304

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110403